to http://www.elivpharma.com
presented by BuyersGuideChem
pr

Shanghai Eliv Pharmaceutical Co., Ltd.

„2,2'-[Sulfonylbis(4,1-phenylenethio)]bisethanethiol is available from stock – feel free to inquire.“    

Company Profile

Shanghai eliv pharmaceutical Co.,Ltd. was founded in 2011. Eliv focus on R&D and production of APIs and intermediates. The major members in the team have Ph.D. or MSEE degrees from prominent universities in China and overseas. Except for first-class production and advanced research facilities, Eliv also has rich experience at intermediates and APIs, analytical method development and impurity research, new drug certificate to declare. Eliv has a comprehensive management system and the production base in Nantong passed the c-GMP certification. Eliv cooperate with domestic famous design institutes to promote the enterprises growing rapidly, boost the existing and developing ability at the market competition. Now, Eliv’s products have been used in cardiovascular and cerebrovascular, anti-cancer, anti-Virus, respiratory system and so on. Major customers include but not limited in Mexico,Spain, Taiwan and so on.

Products

Shanghai Eliv Pharmaceutical Co., Ltd. offers competitive products including
  • 2,2'-[Sulfonylbis(4,1-phenylenethio)]bisethanethiol
The company offers a total of 43 chemical products.

Additional Services

-/-

Address & Contact

location
Shanghai Eliv Pharmaceutical Co., Ltd.
No.4999 Fujing Road, Baoshan Distric
Shanghai
P.R.China
Sales Contact:
Phone:
+86-21-50158063
Fax:
+86-21-60276085
Email:

Website:

Your inquiry to Shanghai Eliv Pharmaceutical Co., Ltd.

Required Product

Your Contact Details


You may insert a short information on your company
The company address, the homepage address and a short company profile.
* required


Information: The mail server will return a copy of this message to you as an acknowledgement.
The data of your company will be stored in a cookie on your computer for repeated use - if you allow cookies.









Chemical-Suppliers
© Copyright 1996 to 2025 by Netvertise GmbH. All rights reserved. Reproduction of any materials from the site is strictly forbidden without permission.